Study detail
Recruiting
Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device
Neurogen Biomarking LLC
Summary
This study compares p-tau217 concentrations in blood collected via the Tasso device versus standard venipuncture in subjects with and without Alzheimer's disease, including a subset with confirmed amyloid pathology.
Eligibility
- Age range
- 40–90 years
- Sex
- All
- Healthy volunteers
- Yes
Detailed criteria
Inclusion Criteria: * AD Amyloid PET/CSF confirmed, healthy control, or amyloid-negative non-AD cognitive impairment Age 40-90 Able to complete Tasso and venipuncture collection Caregiver consent/assistance available if needed Exclusion Criteria: * Uncontrolled systemic conditions Recent surgery/hospitalization (3 months) Other dementia drug trial (2 months) Pregnancy Prior Donanemab or Lecanemab use
Locations (5)
- Insigth Hospital and Medical Center ChicagoChicago, Illinois
- Insight Hospital and Medical Center DearbornDearborn, Michigan
- Insight Institute of Neurology and NeurosurgeryFlint, Michigan
- Memorial Healthcare HospitalOwosso, Michigan
- Wake Forest Baptist Medical CenterWinston-Salem, North Carolina